Short Report

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

Volume 6, Issue 11   November 2010
Pages 881 - 887
http://dx.doi.org/10.4161/hv.6.11.12849
Authors: Christopher J. Gill, Roger Baxter, Alessandra Anemona, Giuseppe Ciavarro and Peter Dull

View affiliations

Abstract:
The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.

Preview:



Advertisements